Jakob, Jens

[["dc.bibliographiccitation.firstpage","810"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology, Biology, Physics"],["dc.bibliographiccitation.lastpage","816"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Wenz, Frederik"],["dc.contributor.author","Dinter, Dietmar J."],["dc.contributor.author","Ströbel, Philipp"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:34:19Z"],["dc.date.available","2020-11-23T13:34:19Z"],["dc.date.issued","2009-11-01"],["dc.description.abstract","To evaluate the toxicity and efficacy of preoperative intensity-modulated radiotherapy (IMRT) combined with temozolomide to improve local tumor control in soft-tissue sarcoma (STS)."],["dc.identifier.doi","10.1016/j.ijrobp.2008.11.032"],["dc.identifier.pmid","19307066"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69018"],["dc.language.iso","en"],["dc.relation.eissn","1879-355X"],["dc.relation.issn","0360-3016"],["dc.title","Preoperative intensity-modulated radiotherapy combined with temozolomide for locally advanced soft-tissue sarcoma"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","10554"],["dc.bibliographiccitation.issue","15, Suppl."],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","32"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Menge, Franka"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Mathew, Monika"],["dc.contributor.author","Marx, Alexander"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Reichardt, Peter"],["dc.contributor.author","Wardelmann, Eva"],["dc.date.accessioned","2020-11-23T13:33:34Z"],["dc.date.available","2020-11-23T13:33:34Z"],["dc.date.issued","2014"],["dc.identifier.doi","10.1200/jco.2014.32.15_suppl.10554"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69010"],["dc.relation.issn","0732-183X"],["dc.relation.issn","1527-7755"],["dc.title","Metastatic pattern of late metastases of gastrointestinal stromal tumors and the contribution radiation therapy for disease control"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","959"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Annals of Surgery"],["dc.bibliographiccitation.lastpage","964"],["dc.bibliographiccitation.volume","267"],["dc.contributor.author","MacNeill, Andrea J."],["dc.contributor.author","Gronchi, Alessandro"],["dc.contributor.author","Miceli, Rosalba"],["dc.contributor.author","Bonvalot, Sylvie"],["dc.contributor.author","Swallow, Carol J."],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Van Coevorden, Frits"],["dc.contributor.author","Rutkowski, Piotr"],["dc.contributor.author","Callegaro, Dario"],["dc.contributor.author","Hayes, Andrew J."],["dc.contributor.author","Honoré, Charles"],["dc.contributor.author","Fairweather, Mark"],["dc.contributor.author","Cannell, Amanda"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Haas, Rick L."],["dc.contributor.author","Szacht, Milena"],["dc.contributor.author","Fiore, Marco"],["dc.contributor.author","Casali, Paolo G."],["dc.contributor.author","Pollock, Raphael E."],["dc.contributor.author","Barretta, Francesco"],["dc.contributor.author","Raut, Chandrajit P."],["dc.contributor.author","Strauss, Dirk C."],["dc.date.accessioned","2020-11-23T13:32:06Z"],["dc.date.available","2020-11-23T13:32:06Z"],["dc.date.issued","2018"],["dc.description.abstract","To investigate the safety of radical resection for retroperitoneal sarcoma (RPS)."],["dc.identifier.doi","10.1097/SLA.0000000000002250"],["dc.identifier.pmid","28394870"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/68992"],["dc.language.iso","en"],["dc.relation.eissn","1528-1140"],["dc.relation.issn","0003-4932"],["dc.title","Postoperative Morbidity After Radical Resection of Primary Retroperitoneal Sarcoma: A Report From the Transatlantic RPS Working Group"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","301"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.lastpage","312"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Golcher, Henriette"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Richter, Stephan"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2021-06-01T09:42:10Z"],["dc.date.available","2021-06-01T09:42:10Z"],["dc.date.issued","2021"],["dc.description.abstract","Background: Data on institutional structures of sarcoma care in Germany are scarce. The utilization of an interdisciplinary tumor board (IDTB) is an essential part of modern cancer care. We investigated to which extent and when IDTB are used in sarcoma care. We hypothesized that IDTB before treatment initiation were used more often at certified cancer centers and at high-volume centers and that IDTB utilization increased over time. Methods: From 2017 to 2020 we conducted a prospective cohort study, undertaking major efforts to include the whole spectrum of sarcoma treatment facilities. To analyze potential predictors of IDTB utilization, we calculated multivariable logistic regressions. Results: Patients and survivors (n = 1,309) from 39 study centers (22 tertiary referral hospitals, 9 other hospitals, and 8 office-based practices) participated; 88.3% of the patients were discussed at some stage of their disease in an IDTB (56.1% before treatment, 78% after therapy, and 85.9% in metastatic disease). Hypotheses were confirmed regarding the utilization of IDTB in certified cancer centers (vs. all others: OR = 5.39; 95% CI 3.28–8.85) and the time of diagnosis (2018/2019 vs. until 2013: OR = 4.95; 95% CI 2.67–9.21). Conclusion:Our study adds to the evidence regarding the institutional structures of sarcoma care in Germany. Utilization of a tumor board before therapy seems to be in an implementation process that is making progress but is far from complete. Certification is a possible tool to accelerate this development."],["dc.identifier.doi","10.1159/000516262"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85163"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.eissn","2296-5262"],["dc.relation.issn","2296-5270"],["dc.title","Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","e009558"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","BMJ Open"],["dc.bibliographiccitation.volume","6"],["dc.contributor.author","Ronellenfitsch, Ulrich"],["dc.contributor.author","Dimitrakopoulou-Strauss, Antonia"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Nowak, Kai"],["dc.contributor.author","Pilz, Lothar R."],["dc.contributor.author","Attenberger, Ulrike"],["dc.contributor.author","Gaiser, Timo"],["dc.contributor.author","Egerer, Gerlinde"],["dc.contributor.author","Fröhling, Stefan"],["dc.contributor.author","Derigs, Hans-Günter"],["dc.contributor.author","Schwarzbach, Matthias"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:32:57Z"],["dc.date.available","2020-11-23T13:32:57Z"],["dc.date.issued","2016-01-06"],["dc.description.abstract","For resectable soft tissue sarcoma (STS), radical surgery, usually combined with radiotherapy, is the mainstay of treatment and the only potentially curative modality. Since surgery is often complicated by large tumour size and extensive tumour vasculature, preoperative treatment strategies with the aim of devitalising the tumour are being explored. One option is treatment with antiangiogenic drugs. The multikinase inhibitor pazopanib, which possesses pronounced antiangiogenic effects, has shown activity in metastatic and unresectable STS, but has so far not been tested in the preoperative setting."],["dc.identifier.doi","10.1136/bmjopen-2015-009558"],["dc.identifier.pmid","26739732"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69004"],["dc.language.iso","en"],["dc.relation.issn","2044-6055"],["dc.title","Preoperative therapy with pazopanib in high-risk soft tissue sarcoma: a phase II window-of-opportunity study by the German Interdisciplinary Sarcoma Group (GISG-04/NOPASS)"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","109"],["dc.bibliographiccitation.journal","Surgical oncology : a review journal of cancer management and research"],["dc.bibliographiccitation.lastpage","112"],["dc.bibliographiccitation.volume","34"],["dc.contributor.author","Weigl, Helene"],["dc.contributor.author","Janssen, Sonja"],["dc.contributor.author","Vassos, Nikolaos"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Simeonova-Chergou, Anna"],["dc.contributor.author","Wenz, Frederik"],["dc.contributor.author","Haubenreisser, Holger"],["dc.contributor.author","Jakob, Jens"],["dc.date.accessioned","2020-11-23T13:30:37Z"],["dc.date.available","2020-11-23T13:30:37Z"],["dc.date.issued","2020-09"],["dc.description.abstract","Local recurrence (LR) of retroperitoneal soft tissue sarcoma (RPS) is a common and life-threatening event. The evaluation of the exact anatomical patterns of local recurrence might help to improve local treatment in RPS."],["dc.identifier.doi","10.1016/j.suronc.2020.04.001"],["dc.identifier.pmid","32891314"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/68977"],["dc.language.iso","en"],["dc.relation.eissn","1879-3320"],["dc.relation.issn","0960-7404"],["dc.title","Fusion imaging to evaluate the radiographic anatomical relationship between primary tumors and local recurrences in retroperitoneal soft tissue sarcoma"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","2624"],["dc.bibliographiccitation.issue","17"],["dc.bibliographiccitation.journal","Cancer : interdisciplinary international journal of the American Cancer Society"],["dc.bibliographiccitation.lastpage","2632"],["dc.bibliographiccitation.volume","122"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Hohenberger, Peter"],["dc.date.accessioned","2020-11-23T13:32:41Z"],["dc.date.available","2020-11-23T13:32:41Z"],["dc.date.issued","2016"],["dc.description.abstract","The management of locally advanced extremity soft tissue sarcoma of the limbs is challenging, particularly for recurrent tumors and those adjacent to neurovascular bundles and joints. Typically, the tumors are large, below the fascia, and high-grade (T2b or stage III according to the American Joint Committee on Cancer) and thus require multimodal therapy. Treatment options must be tailored to patient and tumor characteristics. Isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan (TNF-ILP) adds a therapeutic option to radiation therapy (RT) and systemic chemotherapy. Although the procedure is somewhat sophisticated to learn, it is a safe method and has been used now for almost 2 decades at more than 50 centers worldwide. TNF-ILP yields a high rate of complete or nearly complete pathologic tumor remission. In combination with surgical resection of the tumor remnant after isolated limb perfusion, the limb salvage rate is close to 90%. Often, patients can be spared adjuvant RT without long-term local tumor control rates being compromised. Nevertheless, TNF-ILP has never been compared with another treatment regimen in a randomized trial. This review summarizes the mode of action and standard application of TNF-ILP and focuses on a critical discussion of the role of TNF-ILP in the multimodal treatment of locally advanced primary and recurrent extremity sarcoma. Cancer 2016. © 2016 American Cancer Society. Cancer 2016;122:2624-2632. © 2016 American Cancer Society."],["dc.identifier.doi","10.1002/cncr.29991"],["dc.identifier.pmid","27197621"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/69000"],["dc.language.iso","en"],["dc.relation.eissn","1097-0142"],["dc.relation.issn","0008-543X"],["dc.title","Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma"],["dc.type","journal_article"],["dc.type.internalPublication","no"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Der Onkologe"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Singer, Susanne"],["dc.contributor.author","Hornemann, Beate"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Arndt, Karin"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2022-04-01T10:02:16Z"],["dc.date.available","2022-04-01T10:02:16Z"],["dc.date.issued","2022"],["dc.description.abstract","Zusammenfassung Hintergrund Knochensarkome sind eine Gruppe sehr seltener maligner Tumoren. Es existieren nur wenige Studien zur psychischen Belastung der betroffenen Patienten. Ziel war es, die Prävalenz erhöhter psychischer Belastung in dieser Gruppe zu ermitteln, damit assoziierte Faktoren zu untersuchen und die Inanspruchnahme psychoonkologischer Angebote zu erfassen. Methode Die Kohortenstudie PROSa (Krankheitslast und Versorgungssituation bei Sarkomen) wurde zwischen 2017 und 2020 in 39 deutschen Studienzentren durchgeführt. Für die vorliegende Analyse wurden Baseline-Querschnittsdaten von erwachsenen Knochensarkompatienten ausgewertet. Die psychische Belastung wurde mit dem Patient Health Questionnaire (PHQ-4) evaluiert. Sozioökonomische und klinische Faktoren wurden als mögliche Prädiktoren erhöhter psychischer Belastung mit multivariablen logistischen Regressionsmodellen exploriert. Resultate Bei den 194 eingeschlossenen Patienten betrug die Prävalenz von Ängsten 18 %, die von Depressivität 22 %. Insgesamt waren 29 % der Patienten überschwellig psychisch belastet. 23 % hatten eine psychoonkologische Betreuung in Anspruch genommen. Im vollen Modell waren arbeitslose Patienten (Odds Ratio [OR] 5,7; 95 %-Konfidenzintervall [CI] 1,6–20,0) und Patienten mit Erwerbsminderungsrente (OR 3,6; 95 %-CI 1,03–12,9) im Vergleich zu solchen in Beschäftigung häufiger belastet, Patienten mit Altersrente, in Vorruhestand oder in Altersteilzeit dagegen weniger häufig (OR 0,2; 95 %-CI 0,05–0,9). Die Häufigkeit psychischer Belastung war bei Patienten 5 Jahre nach Diagnose (Vergleich Diagnose < 6 Monate) geringer (OR 0,1; 95 %-CI 0,04–0,4). Konklusion Die Prävalenz erhöhter psychischer Belastung bei Knochensarkompatienten ist hoch. Arbeitslose Patienten, solche mit Erwerbsminderungsrente sowie neu diagnostizierte Patienten sind besonders vulnerabel. Das Behandlungsteam sollte sich dieser Faktoren bewusst sein und auch diese sozialen Aspekte der Erkrankung berücksichtigen."],["dc.identifier.doi","10.1007/s00761-022-01098-8"],["dc.identifier.pii","1098"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/105869"],["dc.language.iso","de"],["dc.notes.intern","DOI-Import GROB-530"],["dc.relation.eissn","1433-0415"],["dc.relation.issn","0947-8965"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Psychische Verfassung und psychosoziale Versorgungssituation von Patienten mit Knochensarkomen"],["dc.title.alternative","Resultate einer deutschen multizentrischen Beobachtungsstudie (PROSa)"],["dc.title.translated","Psychological distress and psychosocial treatment situation in patients with bone sarcomas"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","British Journal of Cancer"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Singer, Susanne"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Richter, Stephan"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Grützmann, Robert"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2022-02-01T10:31:08Z"],["dc.date.available","2022-02-01T10:31:08Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment."],["dc.description.abstract","Abstract Background Sarcomas are rare cancers of high heterogeneity. Health-Related Quality of Life (HRQoL) has been shown to be a prognostic factor for survival in other cancer entities but it is unclear whether this applies to sarcoma patients. Patients and methods HRQoL was prospectively assessed in adult sarcoma patients from 2017 to 2020 in 39 German recruiting sites using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). Vital status was ascertained over the course of 1 year. HRQoL domains were analysed by multivariable cox-regressions including clinical and socio-economic risk factors. Results Of 1102 patients, 126 (11.4%) died during follow-up. The hazard ratio (HR) for global health was 0.73 per 10-point increase (95% confidence interval (CI) 0.64–0.85). HR for the HRQoL-summary score was 0.74 (CI 0.64–0.85) and for physical functioning 0.82 (CI 0.74–0.89). There was also evidence that fatigue (HR 1.17, CI 1.10–1.25), appetite loss (HR 1.15, CI 1.09–1.21) and pain (HR 1.14, CI 1.08–1.20) are prognostic factors for survival. Conclusion Our study adds sarcoma-specific evidence to the existing data about cancer survival in general. Clinicians and care-givers should be aware of the relations between HRQoL and survival probability and include HRQoL in routine assessment."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1038/s41416-022-01702-z"],["dc.identifier.pii","1702"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/98790"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-517"],["dc.relation.eissn","1532-1827"],["dc.relation.issn","0007-0920"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients—results of a Nationwide Observational Study (PROSa)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","pon.6009"],["dc.bibliographiccitation.journal","Psycho-Oncology"],["dc.contributor.author","Eichler, Martin"],["dc.contributor.author","Hentschel, Leopold"],["dc.contributor.author","Singer, Susanne"],["dc.contributor.author","Hornemann, Beate"],["dc.contributor.author","Hohenberger, Peter"],["dc.contributor.author","Kasper, Bernd"],["dc.contributor.author","Andreou, Dimosthenis"],["dc.contributor.author","Pink, Daniel"],["dc.contributor.author","Jakob, Jens"],["dc.contributor.author","Arndt, Karin"],["dc.contributor.author","Schuler, Markus K."],["dc.date.accessioned","2022-09-01T09:50:29Z"],["dc.date.available","2022-09-01T09:50:29Z"],["dc.date.issued","2022"],["dc.description.sponsorship"," Deutsche Krebshilfe https://doi.org/10.13039/501100005972"],["dc.identifier.doi","10.1002/pon.6009"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113723"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1099-1611"],["dc.relation.issn","1057-9249"],["dc.rights.uri","http://creativecommons.org/licenses/by/4.0/"],["dc.title","Distress in soft‐tissue sarcoma and gastrointestinal stromal tumours patients—Results of a German multicentre observational study (PROSa)"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]